AU2020296829B2 - Method for treating asthma - Google Patents

Method for treating asthma

Info

Publication number
AU2020296829B2
AU2020296829B2 AU2020296829A AU2020296829A AU2020296829B2 AU 2020296829 B2 AU2020296829 B2 AU 2020296829B2 AU 2020296829 A AU2020296829 A AU 2020296829A AU 2020296829 A AU2020296829 A AU 2020296829A AU 2020296829 B2 AU2020296829 B2 AU 2020296829B2
Authority
AU
Australia
Prior art keywords
asthma
dapansutrile
airway
mice
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020296829A
Other languages
English (en)
Other versions
AU2020296829A1 (en
Inventor
Charles A. Dinarello
Carlo MARCHETTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olatec Therapeutics Inc
Original Assignee
Olatec Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Inc filed Critical Olatec Therapeutics Inc
Publication of AU2020296829A1 publication Critical patent/AU2020296829A1/en
Application granted granted Critical
Publication of AU2020296829B2 publication Critical patent/AU2020296829B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2020296829A 2019-06-17 2020-06-15 Method for treating asthma Active AU2020296829B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962862434P 2019-06-17 2019-06-17
US62/862,434 2019-06-17
PCT/US2020/037696 WO2020257093A1 (en) 2019-06-17 2020-06-15 Method for treating asthma

Publications (2)

Publication Number Publication Date
AU2020296829A1 AU2020296829A1 (en) 2022-02-10
AU2020296829B2 true AU2020296829B2 (en) 2026-01-15

Family

ID=74040873

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020296829A Active AU2020296829B2 (en) 2019-06-17 2020-06-15 Method for treating asthma

Country Status (8)

Country Link
US (1) US20220087969A1 (https=)
EP (1) EP3983070B1 (https=)
JP (1) JP7607939B2 (https=)
CN (1) CN114007690B (https=)
AU (1) AU2020296829B2 (https=)
CA (1) CA3141407A1 (https=)
MX (1) MX2021015561A (https=)
WO (1) WO2020257093A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2651407B1 (en) * 2010-12-15 2016-12-21 Olatec Industries LLC 3-methanesulfonylpropionitrile for treating inflammation and pain
FR3046933B1 (fr) * 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
US11597706B2 (en) * 2016-04-18 2023-03-07 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN SHUYU ET AL: "Blockade of the NLRP3/Caspase-1 Axis Ameliorates Airway Neutrophilic Inflammation in a Toluene Diisocyanate-Induced Murine Asthma Model", TOXICOLOGICAL SCIENCES, vol. 170, no. 2, 17 April 2019, pages 462-475 *
KIM RICHARD Y ET AL: "Role for NLRP3 Inflammasome-mediated, IL-lb-Dependent Responses in Severe, Steroid -Resistant Asthma", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 196, no. 3, 1 August 2017, pages 283-297 *
MARCHETTI ET AL.: "OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation", PNAS, vol. 115, no. 7, 29 January 2018, pages E1530-E1539 *
YANG YANG ET AL: "Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors", CELL DEATH & DISEASE, vol. 10, no. 2, 1 February 2019 *

Also Published As

Publication number Publication date
CN114007690A (zh) 2022-02-01
JP7607939B2 (ja) 2025-01-06
JP2022536932A (ja) 2022-08-22
US20220087969A1 (en) 2022-03-24
CA3141407A1 (en) 2020-12-24
WO2020257093A1 (en) 2020-12-24
MX2021015561A (es) 2022-01-24
EP3983070B1 (en) 2024-09-11
AU2020296829A1 (en) 2022-02-10
EP3983070A4 (en) 2023-04-26
EP3983070A1 (en) 2022-04-20
CN114007690B (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
JP2001518518A (ja) 分泌性白血球プロテアーゼインヒビターの乾燥粉末薬学的組成物
JP2007131635A (ja) 抗線維形成活性を発揮する低分子量ペプチドによる治療
AU2020296829B2 (en) Method for treating asthma
JP2011190274A (ja) 炎症反応により生ずる哺乳動物の鼻および副鼻洞の病気を処置する方法および組成物
JP7309791B2 (ja) イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用
CN1700894A (zh) 使用羊毛硫抗生素治疗干眼病的方法
CN116687907A (zh) 淫羊藿素在制备抑制淀粉样蛋白Aβ诱导阿尔兹海默病药物中的应用
KR20130055580A (ko) 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
CN100394981C (zh) 一种人粒细胞巨噬细胞集落刺激因子喷雾剂及其制备方法
US8697635B2 (en) Pharmaceutical preparation to be administered into respiratory organs for treating or preventing inflammatory respiratory diseases, and method for treating or preventing such diseases
JP2021176903A5 (https=)
CN101057877A (zh) 草珊瑚提取方法、提取物及其药物组合物与用途
KR102872873B1 (ko) 바이러스 감염증 치료용 약학 조성물 및 치료 방법
CN101203229A (zh) 用于治疗或预防由肺泡破坏引起的肺病的克拉霉素或其盐
CN118892484B (zh) 4-氨基-1-苄基哌啶在制备预防和/或治疗急性肺损伤药物中的应用
CN112656794B (zh) 吡咯喹啉醌或其盐在制备用于防治前列腺增生药物中的用途及药物组合物
AU2022285210A1 (en) Compositions and methods for treating respiratory distress
CN108530348A (zh) 一种治疗慢性阻塞性肺疾病的药物及其制备方法
CN120000665A (zh) 雷公藤红素在制备防治ilc2细胞介导的过敏性肺部炎症药物中的应用
Shaikh et al. A Review on Novel Approaches to the Treatment of Asthma
EP4051300A1 (en) Composition for the prevention and treatment of diseases of the respiratory system
JP2022014868A (ja) 慢性閉塞性肺疾患の急性増悪の治療薬の調製におけるＴａｎｒｅｑｉｎｇの応用
HK40030149A (en) Using of tanreqing in the preparation of drugs for the treatment of acute exacerbation of chronic obstructive pulmonary disease
CN111454366A (zh) 一种融合蛋白及其应用